Adverse Events Following. Kevin Connolly Waterford, Aug. 25, 2016

Similar documents
Adverse events following Immunisation Common and Uncommon. Dr Anna Clarke National Immunisation Office September

Adverse Events Following Immunisation. Kevin Connolly Limerick, Sept. 22, 2016

Adverse Events Following Immunisation. Castlebar, Nov. 8, 2013 Kevin Connolly

Adverse Events Following Immunisation

Adverse Events Following Immunisation. Kevin Connolly Castlebar June 27, 2018

Training for Inactivated Poliovirus Vaccine (IPV) introduction. Module 6. Inactivated poliovirus vaccine AEFI monitoring

Vaccine safety messages

Let s talk about protection Childhood Vaccination. Flipbook to support conversations with parents and caregivers

MEASLES, MUMPS, RUBELLA (MMR)

Measles and Measles Vaccine

Routine Office Visits

Safety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist

Lessons Learned from Adverse Events and Assessment of Causal Relationships. Neal A. Halsey Johns Hopkins University

Monitoring Vaccines Introduction. Pia Caduff-Janosa MD May 2013

CHILDHOOD VACCINATION

Priorix TM Measles, mumps and rubella vaccine (live, attenuated)

Assessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University

Childhood immunisation: An Update

A Parent s Guide to Childhood Immunization. Be informed.

Gardasil Network Development Project GARDASIL VACCINE QUESTIONNAIRE

Varicella (Chickenpox) and Varicella Vaccines

Yukon School Immunization Program Grade 9 INFORMATION FOR PARENTS/GUARDIANS

Post Licensure Communication on Vaccine Safety among Regulator, Industry and Stakeholder

MODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE

Immunization Safety Surveillance

Help protect your child. At-a-glance guide to childhood vaccines.

Help protect your child. At-a-glance guide to childhood vaccines.

How do we know vaccines are safe?

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

PHARMACOVIGILANCE GLOSSARY

Viral Vaccines I 5/17/04 LECTURE OUTLINE I. CASE HISTORY

Immunizations Offered

Help protect your child. At-a-glance guide to childhood vaccines.

Vaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013

Thursday, 21 September Vaccine Safety HPV. Helen Petousis-Harris, PhD National Immunisation Workshop Sept 2017

Immunisation in the Bay of Plenty and Lakes

General Recommendations. General Best Practice Guidelines 9/10/2018. General Best Practice Guidelines for Immunization Part 1

Don t let your child catch it

The National Immunisation Schedule. Dr Brenda Corcoran.

Objectives. Immunity. Diphtheria. Immunization Update July 22, Individual Immunity

Priorix TM Measles, mumps and rubella vaccine

Health Care Workers (HCWs) in Ireland should have 2 doses of MMR vaccine. Two of the cases in recent outbreaks in Ireland were HCWs.

Rotavirus. Factsheet for parents. Immunisation for babies up to a year old

46825 (260) $UPONT

Cyprus Experience. Dr. Elena Papamichael Ministry of Health

The Danish childhood vaccination program SUMMARY IN ENGLISH

SCIENTIFIC DISCUSSION

Vaccination schedules in Denmark

Human Papillomavirus Immunisation Programme. Background

Objectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015

Update on Mumps and Current Status of Outbreak in NW Arkansas

Part 1: Vaccine-Preventable Diseases and Childhood Vaccines

TWINRIX GlaxoSmithKline

VACCINATION PASSIVE IMMUNITY

301 W. Alder, Missoula, MT or

Yukon School Immunization Program Grade 6 INFORMATION FOR PARENTS/GUARDIANS

Immunisation. for babies just after their first birthday

Summary of Key Points

The Ministry of Health recommends measles vaccines for all child care providers, children and parents to ensure they are protected against measles.

Current National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office.

MEASLES, MUMPS, RUBELLA (MMR)

Immunisation for pre-school children. three years and four months old

Help protect your baby against MenB

Application Form/Pre-examination Form for IMOVAX POLIO Subcutaneous Injection For optional vaccination

Faculty of Medicine. Applied Vaccination. Hatim Jaber MD MPH JBCM PhD

Measles, Mumps and Rubella. Ch 10, 11 & 12

The National Immunisation Schedule. Dr Brenda Corcoran.

Vaccines for Children

Faculty of Medicine. Applied Vaccination. Hatim Jaber MD MPH JBCM PhD

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

Postmarketing surveillance of pandemic H1N1 vaccines

2016/17 Vaccination and Immunisation list of additional services and enhanced services

Are you protected against measles mumps and rubella?

HIBERIX PRODUCT INFORMATION

To view an archived recording of this presentation please click the following link:

C o n t e n t s. > Immunizations 4. > Diphtheria 6. > Pertussis 7. > Tetanus 8. > Polio 9. > Measles 10. > Tuberculosis 11.

DESCRIPTION OF MUMPS

Who makes these rules? 04/19/2013. Guidelines for vaccine schedules Vaccine information materials Worksheets for assessing immunization i records

Summary of product characteristics As per Annexure C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1

Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center

Communicable Disease Update; Vol. 16 (1), February 2017

Communicable Disease & Immunization

Community Immunization Education Guide Tool Kit

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Don t let your child catch it

Parents Guide CHILDHOOD IMMUNIZATIONS

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE

Background Rationale of resource Please note:

SAFETY AND EFFICACY ASSESSMENTS

Childhood Immunisation. Information for families of babies and young children

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

vaccines. Lecture 16 Dr. Gary Mumaugh

Expanded Programme on Immunization (EPI)

Immunization Updates, Vaccine Administration, and Safety. Audrey Muñoz, LVN, AAHA Immunization Educator June 20, 2012

CHAD B. PRESTON, M.D. ROCHESTER, NY SHERRY SMITH, P.N.P. NEERU KHANNA, M.D. CHILDHOOD VACCINES

Immunization Manual Pre-Departure Medical Services Interim Federal Health Program

BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.

3/10/2017. Overview N.J.A.C. 8:57-6. Purpose of N.J.A.C. 8:57-6. New Jersey Higher Education Immunization Requirements

Vaccines. Dr. Gary Mumaugh

Transcription:

Adverse Events Following Immunisation Kevin Connolly Waterford, Aug. 25, 2016

Abbreviations ADR adverse drug reaction AE adverse event AEFI adverse event following immunisation SAE serious adverse event SUSAR suspected unexpected serious adverse reaction

Definitions Adverse Drug Reaction A response to a drug which is noxious and unintended, occurs at doses normally used for the prophylaxis,.. or therapy of disease, Adverse Event Any untoward medical occurrence that may present during treatment with a pharmaceutical product tbut which h does not necessarily have a causal relationship with this treatment

Definitions Adverse Event Following Immunization (AEFI) Any untoward medicaloccurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine. The adverse event may be any unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.

AEFI 1. Loose definition to encourage reporting does not restrict type of event does not limit the time after immunisation events, not reactions, arereportedreported 2. Belief that immunisation was responsible may be correct, incorrect, or impossible to assess 3. Does not imply causality

AEFIs Mild Reactions Common Include pain, swelling, fever, irritability, malaise Self limiting, limiting seldom requiring symptomatic treatment But important to inform parents about such events so they know about them

Serious Adverse Event Fatal Life threatening Permanently/significantly disabling Requires hospitalisation Causes a congenital abnormality Requires intervention to prevent permanent impairment or damage

Frequency of Reactions Very common.. >10% Common..1 10% 10% Uncommon.1/100 1/1,000 Rare..1/1,000 1/10,000 1/10 Very rare.<1/10,000

Known AEFIs More Common Less Common (>1 in 100) (<1/100) Rd Redness Encephalitis Swelling, nodule Paralysis Pi Pain Arthritis i Fever, irritability, loss of Allergic reaction appetite, nausea, D+V Thrombocytopoenia Febrile seizure Fainting Narcolepsy Death

What is Less Common? Frequency of known injury* What else is this common? 1/1,000 to 1/100,000 Fainting or collapse Having Febrile seizure quadruplets Thrombocytopoenia 1/100,000 to 1/1,000,000 Serious allergic reaction Getting struck Arthritis by lightning >1 in a million Encephalitis Paralysis Death *highest rate for any childhood vaccine Winning the lottery

Febrile Seizures and Vaccines Influenza, DTaP, PCV vaccines given together febrile seizures in up to 30/100,000 immunised If you vaccinate 1000 children <5 including 300 500 between 6 and 24 months of age annually Expect to see at most 1 febrile seizure every 5 to 10 years 30 to 75 of the vaccinated children would get febrile seizure from other causes Not vaccinated may get illnesses

Febrile Seizures and Vaccines Influenza, DTaP, PCV vaccines given together febrile seizures in up to 30/100,000 immunised If you vaccinate 1000 children <5 including 300 500 between 6 and 24 months of age annually Expect to see at most 1 febrile seizure every 5 to 10 years 30 to 75 of the vaccinated children would get febrile seizure from other causes Not vaccinated may get illnesses

Febrile Seizures and Vaccines Influenza, DTaP, PCV vaccines given together febrile seizures in up to 30/100,000 immunised If you vaccinate 1000 children <5 including 300 500 between 6 and 24 months of age annually Expect to see at most 1 febrile seizure every 5 to 10 years 30 to 75 of the vaccinated children would get febrile seizure from other causes Not vaccinated may get illnesses

Febrile Seizures and Vaccines Influenza, DTaP, PCV vaccines given together febrile seizures in up to 30/100,000 immunised If you vaccinate 1000 children <5 including 300 500 between 6 and 24 months of age annually Expect to see at most 1 febrile seizure every 5 to 10 years 30 to 75 of the vaccinated children would get febrile seizure from other causes Not vaccinated may get illnesses

Febrile Seizures and Vaccines Influenza, DTaP, PCV vaccines given together febrile seizures in up to 30/100,000 immunised If you vaccinate 1000 children <5 including 300 500 between 6 and 24 months of age annually Expect to see at most 1 febrile seizure every 5 to 10 years 30 to 75 of the vaccinated children would get febrile seizure from other causes Not vaccinated may get illnesses

Febrile Seizures and Vaccines Febrile seizures frightening, sequelae rare Giving vaccines simultaneously less visits, pain, irritability Assurance that children fully immunized and protected Missed vaccines may never be administered Infec ons may serious illness, seizures.

What Causes AEFIs? Vaccine due to vaccine s inherent properties p Programme, administration Injection reaction anxiety or pain of injection Unknown cause cannot be determined

AEFIs: potential sources Manufacturing potency issues over attenuation of live vaccines instability over time reconstitution, mixinginterferences interferences Storage issues Administration issues technique concomittant administrations Patient profile age, g, weight immune deficiency e.g. AIDS Environmental epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues over attenuation of live vaccines instability over time reconstitution, mixinginterferences interferences Storage issues Administration issues technique concomittant administrations Patient profile age, g, weight immune deficiency e.g. AIDS Environmental epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues over attenuation of live vaccines instability over time reconstitution, mixinginterferences interferences Storage issues Administration issues technique concomittant administrations Patient profile age, g, weight immune deficiency e.g. AIDS Environmental epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues over attenuation of live vaccines instability over time reconstitution, mixinginterferences interferences Storage issues Administration issues technique concomittant administrations Patient profile age, g, weight immune deficiency e.g. AIDS Environmental epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues over attenuation of live vaccines instability over time reconstitution, mixinginterferences interferences Storage issues Administration issues technique concomittant administrations Patient profile age, g, weight immune deficiency e.g. AIDS Environmental epidemiology: strain variation

Timing of Vaccine Reactions Inactivated vaccines: generally within 48hrs Live vaccines: according to time for virus to replicate MMR: measles (malaise, fever, rash) in 6 11 days rubella (pain, stiffness, arthritis) in 2 nd week mumps (parotid swelling) in 3 rd week (up to 6 weeks)

Pertussis Pertussis Complications Pertussis Vaccine Condition % Reaction DTwP DTaP Pneumonia 5 (12% in infants <6/12) Convulsions 1.4 Encephalopathy p 0.2 Death (83% <3/12) 0.2 Hospitalisation 30 Pain 25 9 Cry>3 hrs 0.4 0.04 High fever 0.24 0.04 Convulsion 0.02 0.007 Death 0

Presenting Risk Information 1. A serious reaction occurs about t1 to 3 times per 10,000 doses 2. About 1 to 3 children out of 10,000 will experience a serious reaction 3. This vaccine rarely causes serious reactions about 1 to 3 children out of 10,000 who receive it 4. This vaccine is very safe 9,997 children out of 10,000000 who receive it will experience no adverse reaction

Vaccine Safety Studies PHASE I Safety, N 10-100100 tolerability May not involve target population PHASE II Safety, immunogenicity, dosing; in target population N = 100 to 200 PHASE III Safety, immunogenicity, longevity of immune response, concomitant use, efficacy N = 1000s to 10,000s PHASE IV Safety and effectiveness; occurs after licensure N > 100,000.

Number of subjects needed to test for increased relative risk of an adverse event Rate In Vaccinated Population Background rate, 2 fold 10 fold 100 fold general population higher higher higher 1 in 10,000 141,000 5,500 500 1 in 100,000 1,238,000 53,500 2,500 1 in 1,000,000 12,951,500 532,500 23,500 Risk always phrased as less than 1 in X Evans D et al. J Infect Dis. 2009;200:321-8.

Why Monitor AEFIs? No vaccine is 100% safe Safety profile established in pre licensure trials Detectable frequency depends on numbers studied (rule of 3) Rare events require huge numbers Risk / benefit fitbl balance changes over time as incidence falls: VAPP as Society becomes more critical

Reporting AEFIs 1 10% are reported Up to 99% are not reported Safety is provisional at time of licencing Rotashield, Vioxx, Pandemrix, HRT, etc If in doubt, write one out Every report is important

Reporting AEFIs

AEFI Coincidence or Vaccine Injury? Some adverse events are caused by the vaccine, some are coincidental All health problems after vaccination Health problems caused by the vaccine

Coincidence or Cause? Is Sequence Consequence? A Exposure (Vaccine, Drug, Diet, Occupation etc) Time B Disease Direct and only cause? One of multiple potential causes? Co factor/indirect cause, trigger? Coincidental?

Vaccine Scares P h d S ll i Punch and Smallpox vaccine Kulenkampff and Pertussis vaccine Wakefield and MMR Nigeria and OPV POTS, CRPS, CFS and HPVV

Correlation between Ice Cream Consumption and Drowning

Correlation is not Causation

Causal Relationship (Bradford Hill Criteria) 1. Temporal relationship 2. Strength of the association 3. Biologic plausibility 4. Dose response relationship 5. Replication of the findings 6. Effect of removing the exposure 7. Alternate explanations considered 8. Specificity of the association 9. Consistency with other knowledge

Problems with Beliefs S li ll ibili bi Sampling, recall, susceptibility bias Symptoms collated Verification of symptoms Incidence of CSF before and after introduction of HPV vaccines EMA assessment Incidence of HPV related cancers Effectiveness of HPV vaccine

One is entitled to one s beliefs and feelings, but not to one s own science The overwhelming body of scientific evidence is that there is no causative association between HPV vaccines and POTS, CFS or CRPS

Minimising Errors Right patient Right vaccine and diluent Righttime time (age,interval, expiry) Right dose Right site Right route Right documentation